001     875374
005     20210130004924.0
024 7 _ |a 10.1136/jnnp-2019-322614
|2 doi
024 7 _ |a 0022-3050
|2 ISSN
024 7 _ |a 0266-8637
|2 ISSN
024 7 _ |a 0368-329X
|2 ISSN
024 7 _ |a 1468-330X
|2 ISSN
024 7 _ |a 2128/25316
|2 Handle
024 7 _ |a altmetric:81449598
|2 altmetric
024 7 _ |a pmid:32371534
|2 pmid
024 7 _ |a WOS:000545962100005
|2 WOS
037 _ _ |a FZJ-2020-01988
082 _ _ |a 610
100 1 _ |a Jost, Stefanie Theresa
|0 0000-0003-0477-2289
|b 0
|e Corresponding author
245 _ _ |a A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up
260 _ _ |a London
|c 2020
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1595006828_26338
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in Parkinson’s disease (PD).Methods Here we report the 36-month follow-up of a prospective, observational, controlled, international multicentre study of the NILS cohort. Assessments included NMSScale (NMSS), PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). Propensity score matching resulted in a pseudo-randomised sub-cohort balancing baseline demographic and clinical characteristics between the STN-DBS and MED groups. Within-group longitudinal outcome changes were analysed using Wilcoxon signed-rank and between-group differences of change scores with Mann-Whitney U test. Strength of clinical responses was quantified with Cohen’s effect size. In addition, bivariate correlations of change scores were explored.Results Propensity score matching applied on the cohort of 151 patients (STN-DBS n=67, MED n=84) resulted in a well-balanced sub-cohort including 38 patients per group. After 36 months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor examination and -complications and reduced LEDD. Significant between-group differences, all favouring STN-DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor examination and PDQ-8 (moderate effects). Furthermore, significant differences were found for the sleep/fatigue, urinary (large effects) and miscellaneous NMSS domains (moderate effects). NMSS total and PDQ-8 change scores correlated significantly.Conclusions This study provides Class IIb evidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with quality of life improvements. This highlights the importance of NMS for DBS outcomes assessments.
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Sauerbier, Anna
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Visser-Vandewalle, Veerle
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Ashkan, Keyoumars
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Silverdale, Monty
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Evans, Julian
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Loehrer, Philipp A
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Rizos, Alexandra
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Petry-Schmelzer, Jan Niklas
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Reker, Paul
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Fink, Gereon Rudolf
|0 P:(DE-Juel1)131720
|b 10
700 1 _ |a Franklin, Jeremy
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Samuel, Michael
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Schnitzler, Alfons
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Barbe, Michael Thomas
|0 P:(DE-Juel1)131613
|b 14
700 1 _ |a Antonini, Angelo
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Martinez-Martin, Pablo
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Timmermann, Lars
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Ray-Chaudhuri, K.
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Dafsari, Haidar S
|0 0000-0001-8849-4233
|b 19
|e Corresponding author
773 _ _ |a 10.1136/jnnp-2019-322614
|g p. jnnp-2019-322614 -
|0 PERI:(DE-600)1480429-3
|n 7
|p 687-694
|t Journal of neurology, neurosurgery, and psychiatry
|v 91
|y 2020
|x 1468-330X
856 4 _ |y Restricted
|u https://juser.fz-juelich.de/record/875374/files/Jost_2020_J%20Neurol%20Neurosurg%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non-motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinson%E2%80%99s%20disease-1.pdf
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/875374/files/Jost_2020_Post%20Print_Neurosurgery%20and%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non%20motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinsons%20disease.pdf
856 4 _ |y Restricted
|x pdfa
|u https://juser.fz-juelich.de/record/875374/files/Jost_2020_J%20Neurol%20Neurosurg%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non-motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinson%E2%80%99s%20disease-1.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/875374/files/Jost_2020_Post%20Print_Neurosurgery%20and%20Psychiatry_A%20prospective%2C%20controlled%20study%20of%20non%20motor%20effects%20of%20subthalamic%20stimulation%20in%20Parkinsons%20disease.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:875374
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 10
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL NEUROSUR PS : 2017
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL NEUROSUR PS : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21